%D9%86%D9%8A%D9%84%D8%A7%D8%B1%D8%A7%D8%A8%D9%8A%D9%86%D9%86%DB%8C%D9%84%D8%A7%D8%B1%D8%A7%D8%A8%DB%8C%D9%86Category:NelarabineNelarabinNelarabineN%C3%A9larabineNelarabin%E3%83%8D%E3%83%A9%E3%83%A9%E3%83%93%E3%83%B3NelarabinaNelarabin%C4%83%D0%9D%D0%B5%D0%BB%D0%B0%D1%80%D0%B0%D0%B1%D0%B8%D0%BDNelarabinNelarabinNelarabineQ1216264
about
sameAs
Nelarabine in the treatment of refractory T-cell malignanciesProfile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemiaNelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma.Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.Precursor T-Cell acute lymphoblastic leukemia/lymphoma with rare presentation in the urinary bladder.Educational paper. The development of new therapies for pediatric oncology.New nucleoside analogs for patients with hematological malignancies.Treatment of acute lymphoblastic leukemia in adults.[Method of determination of the proteolytic activity with the aid of ninhydrin]In vitro efficacy of forodesine and nelarabine (ara-G) in pediatric leukemia.Towards the development of a rapid, portable, surface enhanced Raman spectroscopy based cleaning verification system for the drug nelarabine.A new high-performance liquid chromatography method determines low production of 9-beta-D-arabinofuranosylguanine triphosphate, an active metabolite of nelarabine, in adult T-cell leukemia cells.High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation[Phase I study of nelarabine in patients with relapsed or refractory T-ALL/T-LBL]
P921
Q24569660-ABF1A95A-442C-4BFE-9EE7-FAE37EC55030Q24633723-86CCFCE5-7EA5-4713-A6A9-07EA1FAC7D26Q33386616-6914999B-D9F3-47DE-9301-03BFE1E09EB2Q34012525-0467D213-C13E-43AF-A1B5-396BE2CDF0C6Q34620283-918AC314-9F9C-4123-944B-2CD359544D72Q35615374-FFB15BEA-D270-4D70-B653-494C5D23FBECQ37824438-A57F9566-B108-4930-AA9B-0EC1D5248EE7Q37841589-65FD9856-9153-4F8A-AD50-460D27ABD7FAQ37847380-13811BFE-0ACC-42B2-B006-139C472B1CC1Q39412724-9FDB6BFF-9D6F-4A66-B8DB-20313853F7DEQ39512415-7DD97E56-326D-49BD-90E5-127E27FBDC18Q42925001-1B9C1F48-2678-457E-B8F2-2E18A0C89353Q43204430-0D5E943F-93E3-4247-9B52-734F3C863E96Q84470178-26935C04-A0EB-4969-B3A5-B5481E20BA81Q84520297-BC5D5BC5-161D-46DD-AAB7-C16998D049B5
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Nelarabin
@de
Nelarabin
@hu
Nelarabin
@sh
Nelarabin
@sr
Nelarabina
@pl
Nelarabine
@vi
Nelarabină
@ro
nelarabine
@en
nélarabine
@fr
Неларабин
@ru
type
label
Nelarabin
@de
Nelarabin
@hu
Nelarabin
@sh
Nelarabin
@sr
Nelarabina
@pl
Nelarabine
@vi
Nelarabină
@ro
nelarabine
@en
nélarabine
@fr
Неларабин
@ru
altLabel
2-Amino-9-beta-D-arabinofuranosyl-6-methoxy-9H-purine
@en
506U78
@en
Arranon®
@en
Atriance®
@en
NLR506
@en
Nelarabine
@en
Nelzarabine
@en
prefLabel
Nelarabin
@de
Nelarabin
@hu
Nelarabin
@sh
Nelarabin
@sr
Nelarabina
@pl
Nelarabine
@vi
Nelarabină
@ro
nelarabine
@en
nélarabine
@fr
Неларабин
@ru